Basilea Pharmaceutica AG (OTCMKTS:BPMUF) shares reached a new 52-week high on Wednesday . The stock traded as high as $60.05 and last traded at $60.05, with a volume of 35 shares trading hands. The stock had previously closed at $54.49.
Several equities analysts recently weighed in on BPMUF shares. Zacks Investment Research cut shares of Basilea Pharmaceutica from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. ValuEngine cut shares of Basilea Pharmaceutica from a “buy” rating to a “hold” rating in a research note on Wednesday.
The company’s 50-day simple moving average is $49.16 and its 200 day simple moving average is $43.11.
About Basilea Pharmaceutica (OTCMKTS:BPMUF)
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand.
See Also: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.